As blockbuster drugs approach patent expiration, life sciences companies face significant revenue risk. Strategic patent portfolio management, validity analysis, and innovation planning can help organizations protect value and maintain competitive advantage beyond loss of exclusivity.

We’ve just returned from the Life Sciences Strategy Summit in Munich, where Keisha Hylton-Rodic joined global experts to explore divisional patenting and the evolving IP landscape. The conversations were rich, the insights actionable, and the collaboration inspiring.